Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

advanced non-small cell lung cancer (nsclc), egfr exon 19 deletion mutation, egfr exon 21 mutation, egfr exon 21 l858r mutation, egfr sensitive mutation, minimal residual disease, mrd dynamic monitoring, befotinib, advanced non-small cell lung cancer, targeted therapy plus chemotherapy, interventional, phase2